266 related articles for article (PubMed ID: 20607237)
1. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells.
Dubrot J; Portero A; Orive G; Hernández RM; Palazón A; Rouzaut A; Perez-Gracia JL; Hervás-Stubbs S; Pedraz JL; Melero I
Cancer Immunol Immunother; 2010 Nov; 59(11):1621-31. PubMed ID: 20607237
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal cytotoxic T lymphocyte hybridomas capable of specific killing activity, antigenic responsiveness, and inducible interleukin secretion.
Kaufmann Y; Berke G
J Immunol; 1983 Jul; 131(1):50-6. PubMed ID: 6190926
[TBL] [Abstract][Full Text] [Related]
3. [Study of anticancer human monoclonal antibody--establishment of human monoclonal antibody to gastric cancer by human-mouse hybridoma].
Liu H
Zhonghua Zhong Liu Za Zhi; 1988 Jul; 10(4):242-4. PubMed ID: 3248478
[TBL] [Abstract][Full Text] [Related]
4. A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones.
Pierres A; Naquet P; Van Agthoven A; Bekkhoucha F; Denizot F; Mishal Z; Schmitt-Verhulst AM; Pierres M
J Immunol; 1984 Jun; 132(6):2775-82. PubMed ID: 6202760
[TBL] [Abstract][Full Text] [Related]
5. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
[TBL] [Abstract][Full Text] [Related]
6. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
Rapp L; Fuji H
Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
[TBL] [Abstract][Full Text] [Related]
7. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
8. Mapping of SJL/J reticulum cell sarcoma tumor-associated Ia antigens by T cell hybridomas: characterization of tumor-specific and shared epitopes detected on IE+ allogeneic cells.
Ohnishi K; Bonavida B
J Immunol; 1986 Jul; 137(2):733-40. PubMed ID: 2424977
[TBL] [Abstract][Full Text] [Related]
9. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
10. Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.
Tirapu I; Arina A; Mazzolini G; Duarte M; Alfaro C; Feijoo E; Qian C; Chen L; Prieto J; Melero I
Int J Cancer; 2004 May; 110(1):51-60. PubMed ID: 15054868
[TBL] [Abstract][Full Text] [Related]
11. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.
Murillo O; Arina A; Hervas-Stubbs S; Gupta A; McCluskey B; Dubrot J; Palazón A; Azpilikueta A; Ochoa MC; Alfaro C; Solano S; Pérez-Gracia JL; Oyajobi BO; Melero I
Clin Cancer Res; 2008 Nov; 14(21):6895-906. PubMed ID: 18980984
[TBL] [Abstract][Full Text] [Related]
13. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
14. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
15. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
Tongu M; Harashima N; Tamada K; Chen L; Harada M
Cancer Sci; 2015 Jan; 106(1):9-17. PubMed ID: 25363339
[TBL] [Abstract][Full Text] [Related]
16. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
[TBL] [Abstract][Full Text] [Related]
19. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
20. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.
Sánchez-Paulete AR; Cueto FJ; Martínez-López M; Labiano S; Morales-Kastresana A; Rodríguez-Ruiz ME; Jure-Kunkel M; Azpilikueta A; Aznar MA; Quetglas JI; Sancho D; Melero I
Cancer Discov; 2016 Jan; 6(1):71-9. PubMed ID: 26493961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
